Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04300686 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Pilot Study in Severe Patients With Takayasu Arteritis.

StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated August 10, 2021 (before its estimated May 1, 2022 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. 2 versions Re-verified since Nov 19, 2020, no change to tracked fieldsv5-v6
  2. Secondary endpoints: details revised at 1 of 7 entries
    • Study description expanded, about 139 words
    v4
  3. Eligibility criteria expanded, about 15 words
    • Secondary endpoints: details revised at 1 of 7 entries
    • Study description shortened, about 4 words
    v3
  4. Secondary endpoints: 6 to 7
    • Study description expanded, about 8 words
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Takayasu arteritis (TAK) is a rare chronic inflammatory arteritis, which lacks an effective well-accepted intervention strategy. We classify TAK patients into 3 levels, including mild, moderate, and severe. And the biological agents tocilizumab and adalimumab are randomly prescribed in severe patients, to find out the relatively better treatment strategy, facilitating better intervention strategy in severe TAK patients.
Trial Details
NCT Number NCT04300686
Lead Sponsor Shanghai Zhongshan Hospital
Conditions
(from sponsor)		 Takayasu Arteritis, Tocilizumab, Adalimumab, Treatment
Related terms Takayasu Arteritis
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov